论文部分内容阅读
目的分析慢性乙型肝炎病理结果与抗病毒疗效的关系。方法经数字表法随机选取2014年2月至2016年2月于本院就诊的慢性乙型肝炎患者150例,根据肝活检结果分为轻度组、中度组和重度组3组,所有患者均接受口服拉米夫定抗病毒治疗,分析慢性乙型肝炎病理结果与抗病毒疗效的关系。结果治疗12周、24周和48周后,3组患者的HBeAg血清转换率和HBV-DNA转阴率均有所提高,且重度组高于中度组,中度组高于轻度组,组间差异(P>0.05);治疗12周、24周和48周后,3组患者ALT复常率变异率均有所提高,且治疗48周后重度组、中度组ALT复常率分别为74.00%和66.00%。显著高于轻度组的40%(P<0.05)。治疗12周、24周和48周后,3组YMDD变异率均有所提高,组间差异(P>0.05)。结论抗病毒治疗疗效和慢性乙型肝炎病理结果与抗病毒疗效存在一定的相关性,对指导抗病毒治疗而言意义显著。
Objective To analyze the relationship between pathological results of chronic hepatitis B and antiviral efficacy. Methods 150 cases of chronic hepatitis B patients admitted to our hospital from February 2014 to February 2016 were randomly selected by digital table. According to the results of liver biopsy, the patients were divided into three groups: mild group, moderate group and severe group. All patients All received oral lamivudine antiviral therapy, analysis of chronic hepatitis B pathological results and the relationship between anti-virus efficacy. Results After 12 weeks, 24 weeks and 48 weeks of treatment, the HBeAg seroconversion rate and HBV-DNA negative conversion rate of the three groups were all improved, and the severe group was higher than the moderate group, the moderate group was higher than the mild group, (P> 0.05). After 12 weeks, 24 weeks and 48 weeks of treatment, the variability of ALT normalization rate was improved in all three groups. After 48 weeks of treatment, the ALT normalization rates in severe group and moderate group were respectively 74.00% and 66.00%. Significantly higher than the mild group of 40% (P <0.05). After 12 weeks, 24 weeks and 48 weeks of treatment, the YMDD mutation rates of the three groups were all improved, with a significant difference between the two groups (P> 0.05). Conclusion The curative effect of antiviral therapy and the pathological result of chronic hepatitis B are related to the anti-virus efficacy, which is of great significance for guiding the anti-virus treatment.